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INTRODUCTION 
―Esophageal varices are porto-systemic collaterals and they form as a consequence of 
portal hypertension (a progressive complication of cirrhosis), preferentially in the sub 
mucosa of the lower esophagus. Rupture and bleeding from esophageal varices are 
major complications of portal hypertension and are associated with a high mortality 
rate. Variceal bleeding accounts for 10–30% of all cases of upper gastrointestinal 
bleeding.‖ 
 
―Most cirrhotic patients will develop esophageal varices over their life time (5 to 15% 
/ year) and the annual rate of esophageal hemorrhage is 5 to 15%. The frequency of 
esophageal varices varies from 30% to 70% in patients with cirrhosis and 9–36% of 
patients have what are known as ―high-risk‖ varices. Esophageal varices develop in 
patients with cirrhosis at an annual rate of 5– 8% but the varices are large enough to 
pose a risk of  bleeding in only 1–2% of cases. The progression from small to large 
varices is 8% per year. Approximately 30% of patients with esophageal varices will 
bleed within the first year after diagnosis. Despite improved diagnosis and treatment 
for variceal hemorrhage, the mortality rate still remains high (20%-35%). The 
presence of gastroesophageal varices correlates with the severity of liver disease. The 
most important predictor of variceal bleeding is the size of esophageal varices.Larger 
the esophageal varices, the more dangerous they are,since large esophageal varices 
may cause a higher tension on variceal walls.Thus, identication of large-sized 
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esophageal varices, before their first bleeding, is essential to prevent or minimize this 
life threatening complication of liver cirrhosis.‖ 
 
Current guidelines recommend using upper gastrointestinal endoscopy (UGIE) to 
screen all cirrhotic patients at diagnosis for identification of varices at a high risk of 
bleeding.In addition, surveillance endoscopies are recommended every 1-2 years for 
patients with small varices or every 2-3 years for patients with no varices in case of 
compensated cirrhosis and yearly for decompensated cirrhosis. Even though UGIE is 
believed to be the gold standard to diagnose esophageal varices, the use of UGIE has 
its own limitations.First, diagnosis of esophageal varices by UGIE depends on the 
performance of individual endoscopists.Second ,most of the patients who undego 
screening UGIE don’t have varices. Third, unnecessary UGIE screening also increases 
the associated health care costs. Fourth, the application of UGIE is an unpleasant 
procedure to patients. Fifth, it may have detrimental effects such as increasing the risk 
of bleeding and infection. 
 
Due to these problems in using UGIE, some noninvasive means have been proposed 
for prediction of esophageal varices in order to restrict UGIE to the population with 
high risk of variceal bleeding.Accurate identification of patients at the highest risk of 
bleeding allows stratification in an attempt to avoid unnecessary preventive measures 
in 60-75% of patients who will never have variceal bleeding in future. In a limited 
resources setting like ours,where financial constraints are a major problem,predicting 
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the presence and grade of varices by non-invasive methods serves to help a lot in 
various ways.  
 
 
Noninvasive identication of esophageal varices is usually based on regular laboratory 
parameters and clinical signs relevant to liver fibrosis and function, portal 
hypertension and hypersplenism. The noninvasive predictive variables include platelet 
count, Child Pugh, albumin level, albumin globulin ratio AST/platelet ratio 
index[APRI], bilirubin level, serum transaminases, haemoglobin level, total counts, 
platelet count/spleen diameter ratio, prothrombin time,spleen size, portal vein 
diameter, splenic diameter, ascites.  
 
The common features of these noninvasive means that prediction of esophageal 
varices is reproducible, cost effective, simple and quick with no additional burden to 
patients. Even though these variables are clearly preferable to patients, none is 
comparable to UGIE in terms of sensitivity and specificity in prediction of variceal 
hemorrhage. To improve the sensitivity and specificity in variceal prediction, several 
predictive models are proposed using various combinations of the above variables. 
Apparently,the sensitivity and specificity of the currently proposed predictive models 
varies with population, the etiologies of liver cirrhosis and the severity of liver 
disease. 
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AIMS AND OBJECTIVES 
 
To identify and study noninvasive investigative parameters (clinical, 
biochemical,radiological)  that could predict the presence and grades of oesophageal 
varices in cirrhosis patients. 
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REVIEW OF LITERATURE 
―Cirrhosis  an end  result of  wide variety of chronic liver diseases , is a 
histopathologic diagnosis defined as diffuse hepatic fibrosis with the replacement of 
the normal liver architecture by micro or macro nodules. The rate of progression of 
chronic liver disease to cirrhosis may be quite variable, and it depends upon the 
etiology for eg: from weeks in patients with complete biliary obstruction to decades in 
patients with chronic hepatitis C. Initially  it was thought that cirrhosis was 
irreversible; there can be reversal of fibrosis when the underlying insult that has 
caused the cirrhosis has been removed. This is seen with the successful treatment of 
chronic hepatitis C, hemochromatosis who have been successfully treated and in 
patients with alcoholic liver disease who have discontinued alcohol use,biliary 
obstruction.” 
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CAUSES OF CIRRHOSIS  
―In Developed countries the prevalence of alcoholic cirrhosis, NASH cirrhosis (non - 
alcoholic steatohepatitis) and viral cirrhosis, in particular hepatitis C, are all 
increasing. In developing countries, the predominant causes are hepatitis virus B and 
C, but alcohol and autoimmune conditions are also at increase.Various causes of 
cirrhosis are: 
1.alcoholism  
2.chronic viral hepatitis(hepatitis B and C)    
3.autoimmune hepatitis 
4.NASH(non-alcoholic steatohepatitis)  
5.biliary cirrhosis(primary biliary cirrhosis,primary sclerosing 
cholangitis,autoimmune cholangiopathy)  
6.cardiac cirrhosis   
7.inherited metabolic liver disease (hemochromatosis,wilsons disease,alpha 1 
antitrypsin deficiency,)  
8.cryptogenic cirrhosis 
Some patients have more than one cause for cirrhosis (such as alcohol excess and viral 
hepatitis). A large portion of patients (up to 20%) do not have an identifiable cause for 
cirrhosis and are named as cryptogenic cirrhosis‖ 
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MORPHOLOGICAL CLASSIFICATION: 
It can classified based on the nodular size. 
Nodules <3mm are said to be micronodular and >3mm as macronodular 
1. Micronodular or Laennec‖s cirrhosis 
2. Macronodular cirrhosis 
3. Mixed type 
 
PATHOGENESIS 
  
 
Induction of fibrosis occurs with activation of hepaticstellate cells to myofibroblasts 
resulting in the formation of increased amounts of collagen and other components of 
the extracellular matrix leading to architectural distortion inturn resulting in decrease 
in function and mass. 
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CLINICAL FEATURES 
                          Patients may present for the first time with the complications of 
cirrhosis or may be asymptomatic and incidentally be identified during checkup for 
unrelated causes or because of abnormal liver tests 
 
                     In clinical terms., cirrhosis is classified in to 
 
•  Compensated form and 
 
•  Decompensated form, 
 
Decompensation is characterized by cirrhosis complicated by one or more 
following features like  - jaundice, ascites, hepatic encephalopathy, bleeding 
varices. Ascites is usually the first sign of decompensation,whereas these features 
and any complication secondary to Portal hypertension is absent in compensated 
cirrhosis.This distinction clinically is very important because of the implication it 
has in the prognostication and treatment. Compensated cirrhosis patients have 
a ten year survival rate of 50% whereas decompensated patients have a survival 
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rate of about 50% in 18 months. A decompensated patient may become 
compensated when the inciting cause or the precipitating cause is removed 
and thereby the prognosis may improve. Patients who have developed complications 
of their liver disease and have become decompensated should be considered for liver 
transplantation. 
 
COMPENSATED CIRRHOSIS: 
At this stage the cirrhotic process of the liver is not severe enough to alter the 
function significantly and so the patients may be asymptomatic or present with 
non-localizing manifestations or may be picked incidentally due to alteration in 
biochemical parameters or imaging studies Patients may have fatigue, anorexia, 
weight loss, flatulence, dyspepsia, abdominal pain. 
 
 On examination palmar  erythema,  pedal  edema,  spider  naevi,  may  point  
towards  cirrhosis. Abdominal examination may reveal an epigastric mass which 
is the enlarged left lobe of the liver and splenomegaly. Biochemical tests are usually 
within normal limits in this group. The most common LFT abnormality in this group 
include mildly elevated transaminases, or GGT. 
 
Confirmation is by liver imaging or liver biopsy. Factors like bacterial infection, 
trauma, or medications, surgery may precipitate decompensation in a compensated 
cirrhosis. 
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DECOMPENSATED CIRRHOSIS: 
These patients present with ascites, jaundice, altered sensorium,bIeeding 
manifestations. 
SYMPTOMS: 
Presentation in these patients may be with features of jaundice,pedal edema,  
abdominal distension,pruritis.Upper GI bleed  most  commonly result in 
malena,hematemesis.Altered sensorium ranging from sleep disturbances to florid 
confusion and coma because of hepatic encephalopathy. In women, 
menstrual irregularities are common due to anovulation.Men, may manifest 
hypogonadism in the form of impotence, loss of sexual drive, testicular atrophy and 
infertility. 
 
 ―Portal hypertension is an important  complicating feature of decompensated cirrhosis 
and is responsible for the development of ascites and bleeding from esophagogastric 
varices  which  makes cirrhosis decompensated‖ . 
 
 
GENERAL EXAMINATION: 
Decreasing blood pressure — with progression of cirrhosis, mean arterial 
pressure often decreases. Hypertensive patients may become normotensive. 
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Patients can have mild fever  (37.5  -38*C). This is probably because of 
bacteremia due to gram negative organisms.Ongoing hepatocyte  necrosis 
and development of hepatocellular carcinoma may also contribute. 
 
Jaundice (This happens once the functional impairment due to hepatocyte 
destruction has exceeded the process of regeneration. The deeper the jaundice, 
more severe is hepatic decompensation) 
 
Skin findings: 
Bronze piginentation of the skin may throw light on the etiology as it occurs in 
hemochromatosis. 
Presence  of  "vascular  spiders‖ (arterial spiders/spider naevi / spider  
telengiectasia spider angioma),  They are seen in distribution of venous drainage 
areas of superior vena cava. As liver function worsens, new spiders may appear. 
They are more frequently associated with alcoholic cirrhosis. They occur normally 
in pregnancy and in some normal individuals.‖Hepatopulmonary‖ syndrome 
is characterized by multiple spiders and clubbing. 
―Palmar erythema‖: palms are warm and red in colour especially over the 
thenar eminence,hypothenar eminence and the pulp of the fingers.  
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Mechanism of both arterial spiders and palmar erythema may be due to 
estrogen excess. The estrogens are inactivated in the liver.Serum estradiol 
level is normal and serum free testosterone is reduced. Thus the high estradiol 
/Free testosterone ratio may he attributed to these findings. 
―Leukonychia‖  may be related to hypoalbuminemia. 
―Clubbing‖ can occur pan digitally especially with development of hepato 
pulmonary syndrome or in cystic fibrosis.‖Hypertrophic osteoarthropathy‖ has 
also been observed. 
―Dupuytrens contracture‖ may be present.This is characterized by thickened 
palmar fascia resulting from unorganized proliferation of the fibroblasts.  
Head and neck findings- 
Parotid enlargement, alopecia, fetor hepaticus, KF ring in the eyes due to Wilson's 
disease may be present. 
―Fetor hepaticus‖ refers to the breath of the cirrhosis patients that has a sweet 
pungent nature. This is because of presence of mercaptans. 
Chest findings – 
Gynecomastia in males may be seen along with other features of feminization like 
change in the male pattern of pubic hair, loss of axillary hair and chest hair. It is 
because the androstenedione that is synthesized by the adrenals gets aromatized in 
to estrone and finally in to estradiol in the adipose tissue. 
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Abdominal findings- 
Abdominal examination may reveal the presence of ascites, hepatomegaly, splenomegaly, 
and dilated abdominal wall veins. 
―Ascites‖ — Ascites refers to excessive collection of peritoneal fluid. In massive 
ascites fluid thrill may be present where as in moderate ascites shifting dullness is to 
be elicited.If flanks are full it is probably due to ascites and not fat. 
―hepatomegaly‖ -The cirrhotic liver may be enlarged, shrunken or normal sized. 
On palpation, consistency is firm and nodular. Features such as shape, consistency 
are to be better appreciated on palpation as the estimation of liver size 
correlates less accurately with imaging studies. Presence of a palpable liver in 
cirrhosis usually signifies alcoholic liver disease, primary biliary 
cirrhosis, hemochromatosis, transformation into hepatocellular 
carcinoma, Budd Chiari syndrome. 
―Splenomegaly‖- Splenomegaly in cirrhosis is due to congestion resulting from 
portal hypertension.however, correlation between splenic size and portal pressure 
is poor- implicating that there  may be other factors contributing. 
―Caput medusae‖ - With the development of portal hypertension,the portal venous 
blood gets carried through the periumbilical veins in to the umbilical vein 
which becomes patent in cirrhosis ,from there the blood drains in to the upper and 
lower abdominal veins that end up in the systemic circulation .These veins 
become engorged and prominent.Thus the portal blood gets shunted to systemic 
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circulation. This appearance resembles the head (Caput) of the mythical Gorgon 
Medusa thus termed caput medusae. 
Dilated abdominal veins developing in SVC obstruction and IVC obstruction 
should be differentiated from  dilated veins due to cirrhosis.In order to 
distinguish the cause of obstruction direction of flow is to be assessed. In IVC 
obstruction the flow is below upwards whereas in cirrhosis the flow of the blood 
is away from the cause of obstruction direction or flow is to be assessed. In IVC 
obstruction the flow is below upwards. However since these veins in both 
conditions may lack valves, the flow may be bidirectional and the test may be 
misleading. Moreover the dilated veins due to obstruction are more commonly 
seen in the back and loin. 
―Peptic ulcers‖ occur in 11% of cirrhosis patients. Duodenal ulcers are more 
frequentiy encountered than gastric ulcers. Colonization by helicobacter pylori 
is higher in cirrhosis when compared to normal population. Abdominal hernias 
are more common in patients with ascites. They should be repaired only if 
severe enough to cause mortality in alcoholics.Associated chronic pancreatitis  
can be present which may relapse,so this should be considered a differential 
diagnosis in alcoholic cirrhosis patients presenting with abdominal pain. 
Neurological findings - The presence of Asterixis or liver flap indicate the 
presence of hepatic encephalopathy. 
 
Genitourinary findings-   Testicular atrophy in males. 
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Endocrine changes- Hyperglycemia occurs in about 80% of cirrhotic patients in 
the form of glucose intolerance. Only around 10-20% are truly diabetic. 
INVESTIGATIONS: 
LIVER FUNCTION TEST ABNORMALITIES- 
―Aminotransferases‖ — In chronic hepatitis ALT is increased more than AST 
.As hepatitis progresses to cirrhosis ,AST becomes more elevated than ALT and 
thus the ratio of AST to ALT is reversed from <I to greater than 1.In cirrhosis 
patients the enzymes can be within normal values or may become moderately 
elevated. 
  ―Alkaline phosphatase‖ - Alkaline phosphatase enzyme is elevated 2 to 3 times  
normal in cirrhosis. If elevated more than that, primary biliary cirrhosis or 
sclerosing cholangitis should be considered as the etiology. 
 ―Gammaglutamyl transpeptidase‖ — Levels of GGT and alkaline phosphatase  
are usually proportionately elevated.Disproportionately high levels of GGT  
will be seen in alcoholic liver discease.GGT present in the rnicrosomes gets  
induced due to alcohol intake. 
―Bilirubin‖ — In compensated stage of cirrhosis, the bilirubin levels are usually  
normal. Decompensation is characterized by increasing levels of bilirubin  
and it is one of the prognostic indicators used in Child Pugh score.  
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 ―Albumin‖ - Albumin is exclusively synthesised in the liver. With worsening  
cirrhosis, due to the decline in the synthetic function of the liver. Albumin levels 
also fail.It is also one of the prognostic indicators for survival in child pugh scoring 
system. 
―Prothrombin time‖ -Many of the coagulation factors are synthesized in 
liver.Prothrombin time which measures the extrinsic coagulation pathway, is a 
marker for the synthetic function of the liver. Thus coagulopathy worsens as 
cirrhosis progresses. 
Serum electrolytes – “hyponatremia‖ can occur in patients with ascites. Severity 
can be correlated with worsening cirrhosis. 
 
Hematologic abnormalities-Thrornbocytopenia, anemia and lencopenia can 
occur. The earliest abnormality to occur is thrombocytopenia and it is a marker for 
the development of portal hypertension. ―Pancytopenia‖ can even be the presenting 
feature in asymptomatic compensated cirrhosis. This is due to sequestration of the 
cells in the enlarged spleen. Platelet count usually does not fall below 50,000.This 
does not per se cause bleeding but bleeding can get aggravated in the presence 
of coagulopathy. 
―Anemia‖ in cirrhosis is mainly because of upper G1 bleed. Anemia can also 
be present as a result of direct suppression of bone marrow by alcohol,splenic 
sequestration and hemolysis, folate deficiency. 
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Other abnormalities - In cirrhosis, the globulin levels are high. This is because of 
shunting of bacterial antigens in the portal venous blood which are normally 
filtered by the liver in to systemic circulation leading which induces production 
of immunoglobulins. Marked elevations of IgG may point towards the presence 
of autoimmune hepatitis. 
Imaging studies: 
 Cirrhosis can be diagnosed radiologically using ultrasound, portal vein Doppler, CT 
and MRI in specific cases. 
•   Ultrasonography — Ultrasonography is a non-invasive routinely used  
 investigation to diagnose cirrhosis. The size of the liver, the nodularity,  
 the portal vein diameter, presence of ascites and splenomegaly can be  
 assessed. Doppler studies to check the direction of blood flow in the  
 portal vein aids in the diagnosis of portal hypertension. Presence HCC  
 and portal vein thrombosis can also be made out. 
•   CT is not the first choice in the diagnosis of cirrhosis. It may be useful  
 when  investigating  liver  malignancy  or  secondaries  or  pancreatic  
 pathology. 
•       MRI may be useful in hermochromatosis to reveal iron overload. MRA 
        can determine  portal vein flow and dynamics. 
•       Elastography to assess the stiffness of the liver tissue is also available. 
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Liver biopsy: 
The gold standard investigation for diagnosing cirrhosis is liver biopsy 
Nowadays liver biopsy is rarely required to diagnose cirrhosis.Only  certain  
situations  may  require  performing  liver  biopsy  such  as  for 
dermonstrating the underlying metabolic cause of cirrhosis such as NASH, Wilson 
disease, hemochromatosis, and alpha 1 antitrypsin deficiency. 
PROGNOSIS: 
Modified Child-Turcotte-Pugh Store (CTP): This simple scoring system is 
now widely in use in clinical practice, for predicting the prognosis and 
mortality from the major complications of the cirrhosis patients. Even though 
it is not derived based on statistically significant studies and is only derived in 
an empirical manner, this score can predict the outcomes in patients with 
liver cirrhosis with reasonable accuracy.  
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Initially this scoring system was used for the stratification of patients in to risk 
groups before taking them up for portosystermic shunt surgeries. Then in clinical 
practice this system was used to prioritize the patients to be taken up for liver 
transplantation (Child Pugh class B) but now this system has been replaced by 
MELD score for selection of patients for liver transplantation. 
MODEL FOR END STAGE LIVER DISEASE (MELD) SCORE - 
MELD score is a score derived methodologically in order to 
prognosticate the patients with cirrhosis and portal hypertension. This 
score is calculated based on three noninvasively obtained variables: serum 
bilirubin, serum creatinine and PT INR. 
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Patients with cirrhosis are given priority for liver transplantation based on 
this particular score in the United States. Patient with a score more than 10 is to be 
considered for 1iver transplantation. This scoring system has the advantage that it is 
completely objective for assessment of severity of the disease and does not result in 
inter observer variations .Moreover the score has a wider range of values,thereby 
severity can be graded precisely. 
MAJOR COMPLICATIONS OF CIRRHOSIS: 
With the progression of cirrhosis and development of portal hypertension, various 
complications occur as a result of either the decreased synthetic, excretory, 
metabolic functions of the liver and also some secondary to portal hypertension. The 
various complications include: 
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PORTAL HYPERTENSION: 
―Portal hypertension is defined as the elevation of the hepatic venous 
pressure gradient (HVPG)>5 mmHg
.‖
 
Portal hypertension occurs as a result of two processes happening simultaneously: 
I) The altered architecture of the liver due to fibrosis and regenerating nodules,  
results in increased resistance to the flow of portal blood. 
2) Increased blood flow secondary to splanchnic vasodilatation. 
This portal hypertension results in variceal bleeding and ascites. The causes of 
portal hypertension are divided into pre-hepatic, post hepatic and intra-
hepatic causes. 
Pre-hepatic causes are thrombosis of portal vein and splenic vein 
thrombosis which results in development of sinistral hypertension or left sided 
portal hypertension. Portal  vein  thrombosis can  occur secondary to cirrhosis  per 
se,pancreatitis, abdominal trauma, infection or hematological causes such as 
essential thrombocytosis, polycythemia vera, protein C and S deficiency. 
 Post hepatic causes are those affecting the hepatic veins and venous drainage in 
to the heart. Conditions include Budd Chiari syndrome, veno occlusive  disease,  
constrictive  pericarditis,  chronic  right  sided  congestion , restrictive 
cardiomyopathy.Intra-hepatic causes include pre-sinusoidal causes such as 
schistosomiasis, congenital portal fibrosis and post sinusoidal causes including 
veno-occlusive disease and cirrhosis causes sinusoidal form of portal hypertension. 
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Clinically  significant  portal  hypertension  occurs  in  around  60% of cirrhosis 
patients.   
The primary complications of portal hypertension include ascites, bleeding varices  
splenomegaly, hypersplenism etc. Splenomegaly  results  from  congestion  due  
to  increased  portal  pressure. Hypersplenism  with  development  of  
thrombocytopenia  may  be  the  first presentation of portal hypertension even 
before ascites may develop. 
 
PATHOPHYSIOLOGY: 
 
Portal hypertension results due to increased intrahepatic resistance and increased 
portal blood flow. As there is increased hepatic resistance, hepatic compliance 
decreases. Increase in portal pressure causes small changes in blood flow. A normal 
liver can adapt to it. But it can have a prominent stimulatory effect on portal pressure 
in the cirrhotic liver. 
Due to hyperdynamic state there is an increase in portal venous inflow. The Collateral 
vessels get dilated and new vessels sprouts. There is an increase in flow from high 
pressure portal veins to low pressure systemic veins. This process of angiogenesis and 
collateral vessel formation can cause esophageal varices. These changes in portal flow 
and resistance are mainly originating from mechanical and vascular factors. 
 
23 
 
―Mechanical factors‖ include the fibrosis and nodularity of the cirrhotic liver, with 
distortion of the vascular architecture and the remodeling that  occur in the systemic 
and splanchnic vascular systems in response to the chronic increases in flow and shear 
stress that characterize the ―hyperdynamic circulatory state‖.  
 
―Vascular factors‖ include intrahepatic vasoconstriction, which contributes to 
increased intrahepatic resistance, and the splanchnic and systemic vasodilatation that 
accompanies the hyperdynamic circulatory state.This increase in hepatic vascular 
resistance is mainly contributed by decrease in the production of the ―vasodilator NO‖ 
and an increase in the production of the ―vasoconstrictor ET-1‖. 
Other vasoactive mediators, like cysteinyl leukotrienes, thromboxane, angiotensin, 
and hydrogen sulfide, have also been implicated in the development of increased 
intrahepatic resistance in cirrhosis.‖ 
 
―The hyperdynamic circulation is characterized by peripheral and splanchnic 
vasodilatation,reduced mean arterial pressure, and increased cardiac 
output.Vasodilatation, particularly in the splanchnic bed, permits an increase in inflow 
of systemic blood into the portal circulation.Splanchnic vasodilatation is caused in 
large part by relaxation of splanchnic arterioles and ensuing splanchnic hyperemia. 
Studies of experimental portal hypertension have demonstrated that splanchnic 
vascular endothelial cells are primarily responsible for mediating splanchnic 
vasodilatation and enhanced portal venous inflow through excess generation of NO. 
This excess generation of NO and ensuing vasodilatation,hyperdynamic circulation, 
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and hyperemia in the splanchnic and systemic circulation contrasts with the hepatic 
circulation, in which NO deficiency contributes to increased  intrahepatic 
resistance.The vascular factors that contribute to portal hypertension are particularly 
important because they are reversible and dynamic and therefore compelling targets 
for experimental therapies. 
 
One third of the patients with cirrhosis have gastric and oesophageal varices, Thus it 
has become mandatory to screen all patients with established cirrhosis for the 
presence of varices using upper GI endoscopy. The risk of variceal bleed depends 
on several factors like the varices size, severity of cirrhosis, tense ascites, and 
increased wedged hepatic vein pressure. In patients with liver cirrhosis the 
development of portal hypertension may be revealed by the presence of 
thrombocytopenia, appearance of an enlarged spleen, encephalopathy, development 
of ascites and esophageal varices with or without bleeding. CT or MRI abdomen 
can be performed in doubtful cases or interventional radiological procedure to 
determine the free and wedged hepatic vein pressure and the gradient between the two 
can be found out. It is normally 5 mm Hg and if more than 12 mm Hg it signifies 
increased risk of bleeding. Once bleeding occurs acute therapy is to arrest the bleed and 
then followed by prophylaxis against repeated bleeding. Acute management is with 
intravenous fluids and blood products and use of octreotide at a rate of 50-100 
mic/hour. This is followed by endoscopic variceal band ligation till the varices are 
obliterated. Non selective beta-blockers can be used as medical prophylaxis. If  this 
mode of management fails, TIPS can be tried. 
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GASTROESOPHAGEAL VARICES: 
―Varices are dilated and tortous veins that develop commonly within the oesophagus 
and stomach of patients with cirrhosis. They  are Porto-systemic collaterals — ie. 
vascular channels that link the portal venous and the systemic venous circulation and 
develop as a result of portal hypertension (a dreaded complication of cirrhosis), 
preferentially in the submucosa of the lower esophagus and also in stomach.‖ 
 Other Sites of portal collaterals: 
1. Oesophageal and gastric varices 
2. Hemorrhoids. 
3. Caput medusae. 
4. Retroperitoneal sites 
 Rupture and bleeding from esophageal varices  are associated with a high mortality 
rate. Despite improved diagnosis and treatment for variceal hemorrhage, the mortality 
rate still remains high (20%-35%) . Variceal bleeding contributes  to 10–30% of all 
cases of UGI bleeding . 
 
―A cirrhosis patient with no varices has not yet developed portal hypertension, or his 
or her portal pressure is not yet high enough for varices to develop. As portal pressure 
increases, small varices start to develop. With time, as circulation increases, blood 
flow through the varices will increase,leading to formation of  large varices.When the 
expanding force exceeds the maximal wall tension,rupture of varices occur resulting 
in hemetemesis. Thus we need to  modify  the tension of the wall with drugs and other 
measures, to prevent recurrence.‖ 
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EPIDEMIOLOGY: 
 
―Most common location is distal oesophagus,but varices may occur in anywhere along 
the  gastrointestinal tract. Around 50% of patients with cirrhosis may develop 
gastroesophageal varices. Gastric varices are present in 5–33% of patients with portal 
hypertension.The frequency of esophageal varices varies from 30% to 70% in patients 
with Cirrhosis and 9–36% of patients have what are known as ―high-risk‖varices.‖  
 
                        ― Annual rate of development  of varices  in patients with cirrhosis is 
around 5–8%, but the varices are large enough to pose a risk of bleeding in only 1–2% 
of cases.Around 4–30% of patients with small varices will go on to develop large 
varices each year and will therefore be at risk of bleeding. Variceal hemorrhage 
occurs at a yearly rate of 5-15%, and 6-week mortality after variceal hemorrhage is 
about 20%. In general, variceal bleeding ceases spontaneously in 40-50% of patients, 
but incidence of early rebleeding ranges between 30% and 40% within first 6 weeks, 
and about 40% of all rebleeding episodes occur within the first 5 days.‖ 
 
―Gastric varices (GV) bleed less frequently than esophageal varices and are 
responsible for 10-30% of all variceal hemorrhages. However, gastric variceal 
bleeding tends to be more severe with higher mortality. In addition, a high proportion 
of patients, around 35-90%, rebleed after spontaneous hemostasis.The presence of 
gastroesophageal varices correlates with the severity of liver disease.The severity of 
cirrhosis can be scored using the Child–Pugh classification system.40% of Child–
Pugh A patients and 85% of Child–Pugh C patients can have varices.‖ 
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PATHOPHYSIOLOGY: 
 
―Four distinct zones of venous drainage at the gastroesophagealjunction are 
particularly relevant to the formation of esophageal varices. The ―gastric zone‖, which 
extends for 2 to 3 cm below the gastroesophageal junction, comprises veins that are 
longitudinal and located in the submucosa and lamina propria. They come together at 
the upper end of the cardia of the stomach and drain into short gastric and left gastric 
veins.The ―palisade zone‖ extends 2 to 3 cm proximal to the gastriczone into the 
lower esophagus. Veins in this zone run longitudinally and in parallel in 4 groups 
corresponding to the esophageal mucosal folds. These veins anastomose with veins in 
the lamina propria. The perforating veins in the palisade zone do not communicate 
with extrinsic (periesophageal) veins in the distal esophagus,hence more chance of 
bleeding. The palisade zone is the dominant watershed area between the portal and 
systemic circulations.More proximal to the palisade zone in the esophagus is the 
―perforating zone‖, where there is a network of veins. These veins are less likely to be 
longitudinal and are termed ―perforating veins” because they connect the veins in the 
esophageal submucosa and the external veins. The ―truncal zone‖, the longest zone, is 
approximately 10 cm in length, located proximal to the perforating zone in the 
esophagus, and usually characterized by 4 longitudinal veins in the lamina propria and 
they are unlikely to bleed.The periesophageal veins drain into the azygos system, and 
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as a result, an increase in azygos blood flow is a hallmark of portal hypertension. The 
venous drainage of the lower end of the esophagus is through the coronary vein, 
which also drains the cardia of the stomach, into the portal vein.‖ 
 
―The fundus of the stomach drains through short gastric veins into the splenic vein. In 
the presence of portal hypertension,varices may therefore form in the fundus of the 
stomach.Splenic vein thrombosis usually results in isolated ―gastric fundal varices‖. 
Because of the proximity of the splenic vein to the renal vein, spontaneous 
splenorenal shunts may develop and are more common in patients with gastric varices 
than in those with esophageal varices‖. 
 
―The development of gastroesophageal varices requires a portal pressure gradient of at 
least 10 mm Hg. Furthermore, a portal pressure gradient of at least 12 mm Hg is 
thought to be required for varices to bleed; other local factors that increase variceal 
wall tension are also needed  because not all patients with a portal pressure gradient of 
greater than 12 mm Hg bleed. Factors that influence variceal wall tension can be 
viewed in the context of ―Laplace’s law‖: 
                                                            T = Pr/w 
                        T is variceal wall tension 
                        P is the transmural pressure gradient between the variceal and    
esophageal lumen    
                      r is the variceal radius 
                     w is the variceal wall thickness. 
29 
 
―When the variceal wall thins and the varix increases in diameter and pressure, the 
tolerated wall tension is exceeded and the varix ruptures. These physiologic 
observations are manifested clinically by the observation that patients with larger 
varices (r) in sites of limited soft tissue support (w), with elevated portal pressure (P), 
tend to be at greatest risk for variceal rupture from variceal wall tension (T) that 
becomes excessive. One notable site in which soft tissue support is limited is at the 
gastroesophageal junction.‖  
 
―The lack of tissue support and high vessel density may contribute to the greater 
frequency of bleeding from varices at the gastroesophageal junction.The level of 
portal hypertension can be known by measuring portal pressure by HPVG,splenic 
pulp pressure,direct portal vein pressure etc.‖ 
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DIAGNOSIS OF VARICES: 
―Upper GI endoscopy‖ is the most commonly used method and also gold standard to 
detect varices. The consensus is that all patients  diagnosed with cirrhosis of the liver 
should be screened for esophageal varices by endoscopy. Surveillance endoscopies are 
recommended on the basis of the level of cirrhosis and the presence and size of the 
varices .Patients with  
 
Compensated cirrhosis and No varices        -    Every 2–3 years 
Compensated cirrhosis with small varices   -    Every 1–2 years 
Decompensated cirrhosis                              -   Yearly intervals  
 
―Wireless video capsule endoscopy, CT imaging,Doppler ultrasonography, 
radiography/barium swallow of the esophagus and stomach, and portal vein 
angiography and manometry are alternative screening modalities in patients who are 
not candidates for upper endoscopy‖. 
 
ESOPHAGEAL VARICES 
Endoscopic grading of esophageal varices is subjective.Various criteria have been 
used to try to standardize the reporting of esophageal varices. The most commonly 
used criteria are those compiled by the ―Japanese Research Society for Portal 
Hypertension‖. The descriptors include  
 red color signs, 
 color of the varix, 
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 form (size) of the varix, and 
 location of the varix. 
―Red color signs‖ include  
1)  ―red wale markings‖, which are longitudinal whip-like marks on the varix           
2)  ―cherry-red spots‖, which usually are 2 to 3 mm or less in diameter 
3) ―hematocystic spots‖, which are blood-filled blisters 4 mm or greater 
                in diameter  
4) diffuse redness.  
The color of the varix can be white or blue. The form of the varix at endoscopy is 
described most commonly as 
 small and straight(grade I) 
 tortuous and occupying less than one third of theesophageal lumen (grade II) 
 large and occupying more than one third of the esophageal lumen (grade III).  
―Varices can be in the lower third, middle third, or upper third of the esophagus. Of all 
of the aforementioned descriptors, the size of the varices in the lower third of the 
esophagus is the most important. The size of the varices in the lower third of the 
esophagus is determined during withdrawal of the endoscope. Small varices are less 
than 5 mm in diameter, whereas large varices are greater than 5 mm in diameter‖. 
 
 Another grading which is used in this study is the Paquet classification, where varix 
size is graded on a 4-point Likert scale:  
 grade 1 varices are small and flattened by insufflation of air; 
 grade 2 varices are slightly larger and do not flatten; 
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 grade 3 varices are larger but do not touch in the middle of the lumen. 
 grade 4 varices are large and touch each other in the middle of the lumen.  
 
―Grade 1 and 2 are small varices and grade 3 and 4 are large varices.Others  are two 
size ,three size classifications. 
Patients with large esophageal varices, Child-Pugh class C cirrhosis, and red color 
signs on varices have the highest risk of variceal bleeding within 1 year‖ 
 
―Progression from small to large varices‖ are associated with 
• Decompensated cirrhosis (Child-Pugh B/C) 
• Alcoholic cirrhosis 
• Presence of red wale marks at baseline endoscopy (=longitudinal dilated venules 
  resembling whip marks on the variceal surface) 
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Risk factors for ―Initial variceal bleeding‖ episode are: 
• large varices (>5 mm) with red color signs 
• high CTP or MELD score 
• continuing alcohol consumption 
• high hvpg >16 mm hg 
• coagulopathy 
―Variceal haemorrhage‖ is diagnosed on the basis of one of the following findings on 
endoscopy: 
 
 Active bleeding from a varix 
 ―White nipple‖ overlying a varix 
 Clots overlying a varix 
 Varices with no other potential source of bleeding 
 
GASTRIC VARICES: 
  
 “There are three types of classification commonly used for GV.  
1. Sarin’s classification  
2. Hashizome classification  
3. Arakawa’s classification.  
Most commonly used classification is Sarin’s classification of GV.  
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 SARIN’S CLASSIFICATION 
―Gastric varices are less prevalent than esophageal varices and are present in 5%-33% 
of patients with portal hypertension with a reported incidence of bleeding of about 
25% in 2 years, with a higher bleeding incidence for fundal varices.  
Gastric varices are categorized into four types based on the relationship with 
esophageal varices, as well as by their location in the stomach.‖ 
a. Gastroesophageal varix (GOV) type 1: Extension of esophageal varices along 
lesser curve. 
b. Gastroesophageal varix type 2: Extension of esophageal varices along great 
curve.  
c. Isolated gastric varix (IGV) type 1 - Varices in stomach.   
    d. Isolated gastric varix type 2: Varices in  duodenum . 
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―GV drain into the systemic vein via the esophageal-paraesophageal varices 
(gastroesophageal venous system), the inferior phrenic vein (IPV) (gastrophrenic 
venous system), or both. These drainage types generally correspond to the 
classification system of Sarin et al. GOV1 drains via esophageal and paraesophageal 
varices, IGV1 drains via the left IPV, and GOV2 drains via both esophageal varices 
and the IPV. GV form at the hepatopetal collateral pathway that develops secondary 
to localized portal hypertension and drain via the gastric veins, thereby corresponding 
with IGV2 .” 
 
―Risk factors for gastric variceal hemorrhage include the size of fundal varices 
(large,medium,small, defined as 10 mm, 5-10 mm,and 5 mm, respectively), Child 
class (C,B,A), and endoscopic presence of variceal red spots (defined as localized 
reddish mucosal area or spots on the mucosal surfaceof a varix).‖ 
 
TREATMENT : 
―The treatment of portal hypertension is aimed either at reducing portal blood flow 
with pharmacologic agents, such as beta blockers or vasopressin and its analogs, or at 
decreasing intrahepatic resistance with pharmacologic agents, such as nitrates, or by 
radiologic or surgical creation of a portosystemic shunt.Treatment also may be 
directed at the varices with use of endoscopic or radiologic techniques.‖ 
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PHARMACOLOGIC THERAPY: 
―It consist of ―splanchnic vasoconstrictors‖ (vasopressin and analogues,somatostatin 
and analogues, nonselective beta-blockers) and ―venodilators‖ (nitrates). 
Vasoconstrictors act by producing splanchnic vasoconstriction and reducing portal 
venous inflow. Venodilators theoretically act by decreasing intrahepatic and/or 
portocollateral resistance.‖ 
Drugs That Decrease Portal Blood Flow 
 Nonselective β-adrenergic blocking agents 
 Somatostatin and its analogs 
 Vasopressin and terlipressin 
Drugs That Decrease Intrahepatic Resistance 
 α1-Adrenergic blocking agents (e.g., prazosin) 
 Angiotensin receptor blocking agents 
 Nitrates 
 
―However, all available venodilators (e.g., isosorbide mononitrate) have a systemic 
hypotensive effect and the decrease in portal pressure appears to be more related to 
hypotension (i.e., a decrease in flow) rather than a decrease in resistance.The 
combination of a vasoconstrictor and a vasodilator has a synergistic portal pressure 
reducing effect.‖ 
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 ENDOSCOPIC THERAPIES - 
                    ―sclerotherapy or endoscopic variceal ligation (EVL)‖, are local therapies 
that have no effect on either portal flow or resistance.  
SHUNTING THERAPY- 
                     radiological (transjugular intrahepatic portosystemic shunt) or surgical, 
by bypassing the site of increased resistance, markedly reduces portal pressure by 
bypassing the site of increased resistance. 
                                   
                                ―Vasopressin‖ is an endogenous peptide hormone that causes 
splanchnic vasoconstriction, reduces portal venous inflow, and reduces portal 
pressure. This drug is associated with serious systemic side effects. ―Terlipressin‖ is 
another semisynthetic analogue with lesser side effects. 
                                    
                                  ―Somatostatin‖ is a 14–amino acid peptide. Following IV 
injection, somatostatin has a half-life in the circulation of 1 to 3 minutes; therefore, 
longer-acting analogs of somatostatin have been synthesized. The best known of these 
analogs are octreotide, lanreotide, and vapreotide. Somatostatin decreases portal 
pressure and collateral blood flow by inhibiting release of glucagon. Somatostatin also 
decreases portal pressure by decreasing postprandial splanchnic blood flow.‖ 
                                     
                                       ―Octreotide‖ has a half-life in the circulation of 80 to 120 
minutes following iv administraton. Its effect on portal pressure is not prolonged, 
however. Moreover, continuous infusion of octreotide does not decrease portal 
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pressure despite decreasing the postprandial increase in portal pressure. Long-acting 
octreotide does not reliably reduce portal pressure, and side effects with higher doses 
preclude use of this agent for the treatment of portal hypertension. Some randomized 
controlled trials support the view that somatostatin or octreotide may be equivalent in 
efficacy to terlipressin or sclerotherapy for controlling acute variceal bleed. In clinical 
practice, somatostatin or octreotide administration is combined with endoscopic 
management of variceal bleeding‖. 
                                        
                              ― Nonselective beta blockers‖ such as propranolol or nadolol are 
preferred. Blockade of β1-adrenergic receptors in the heart decreases cardiac 
output.Blockade of β2-adrenergic receptors, which cause vasodilatation in the 
mesenteric circulation, allows unopposed action of α1-adrenergic receptors and results 
in decreased portal flow.The combination of decreased cardiac output and decreased 
portal flow leads to a decrease in portal pressure. The effectiveness of beta blockers is 
assessed most accurately by monitoring the HVPG. The acute hemodynamic response 
(decrease in HVPG to < 12 mm Hg, or by 10%) 20 minutes after administration of IV 
propranolol may be used to predict the long-term reduction in bleeding risk. The 
benefit of beta blockers is reduced when hepatic function worsens. The usual method 
of monitoring the efficacy of beta blockers is to observe a decrease in the heart rate, 
which is a measure of β1-adrenergic receptor blockade.‖ 
                                    
                                          ―Carvedilol‖ is a drug that has both nonselective β-blocker 
and weak α-receptor blockade activity. α-Receptor activity normally increases 
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resistance within the intrahepatic circulation. Therefore, blockade of the α-receptor 
decreases intrahepatic vascular resistance, which results in a further reduction in 
portal pressure Carvedilol is also known to have antioxidant as well as 
antiproliferative actions and may be superior to endoscopic variceal ligation in the 
prevention of a first variceal bleed .Carvedilol has been demonstrated to be equivalent 
to a combination of nadolol and isosorbide mononitrate in reducing variceal 
rebleeding, with fewer side effects.Carvedilol is started in a dose of 6.25 mg once 
daily, and the dose is increased stepwise to a maximum of 25 mg daily. Dose 
increases are usually limited by arterial hypotension.‖ 
 
                               ―Nitrates‖-   Short-acting (nitroglycerin) or long-acting (isosorbide 
mononitrate) nitrates result in vasodilatation. The vasodilatation results from a 
decrease in intracellular calcium in vascular smooth muscle cells. Nitrates cause 
venodilatation, rather than arterial dilatation, and decrease portal pressure 
predominantly by decreasing portal venous blood flow. Nitroglycerin has been used in 
combination with vasopressin to control acute variceal bleeding. The rate of infusion 
of nitroglycerin is 50 to 400 μg per minute, provided that the systolic blood pressure is 
greater than 90 mm Hg; however, the combination of vasopressin and nitroglycerin is 
seldom used nowadays. Nitrates are no longer recommended, either alone or in 
combination with a beta blocker, for primary prophylaxis to prevent first variceal 
bleeds. For secondary prophylaxis (to prevent variceal rebleeding), isosorbide 
mononitrate may be added to a beta blocker if the beta blocker alone has not resulted 
in an appropriate decrease in HVPG.‖ 
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                      Drugs like prazosin,losartan,simvastatin may decrease intrahepatic 
resistance. 
 
ENDOSCOPIC THERAPY: 
                                 ―Endoscopic therapy is the only treatment modality that is widely 
accepted for the prevention of variceal bleeding,control of acute variceal bleeding, and 
prevention of variceal rebleeding. Endoscopic variceal therapy includes variceal 
sclerotherapy and band ligation.‖ 
  
 
SCLEROTHERAPY : 
                           
                             ―Endoscopic sclerotherapy has largely been supplanted by 
endoscopic band ligation, except when poor visualization precludes effective band 
ligation of bleeding varices. The technique involves injection of a sclerosant into 
(intravariceal) or adjacent to (paravariceal) a varix.The sclerosants used include 
sodium tetradecyl sulfate,sodium morrhuate, ethanolamine oleate, and absolute 
alcohol.Complications include retrosternal discomfort, sclerosant-induced esophageal 
ulcer-related bleeding, strictures, and perforation‖. 
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VARICEAL LIGATION: 
                              ―Endoscopic variceal ligation is the preferred endoscopic modality 
for control of acute esophageal variceal bleeding and prevention of rebleeding; 
however, the utility of band ligation in the treatment of gastric varices is limited. 
Variceal ligation is simpler to perform than injection sclerotherapy. The procedure 
involves suctioning of the varix into a cap fitted on the tip of an endoscope and 
deploying a band around the varix.The band strangulates the varix, thereby causing 
thrombosis.‖ 
                                          ―Multi-band devices can be used to apply several bands 
without requiring withdrawal and reinsertion of the endoscope.Varices at the 
gastroesophageal junction are banded initially,and then more proximal varices are 
banded in a spiral manner at intervals of approximately 2 cm; the endoscope is then 
withdrawn. Varices in the mid- or proximal esophagus do not need to be banded. 
Endoscopic variceal ligation is associated with fewer complications than sclerotherapy 
and requires fewer sessions to achieve variceal obliteration. Moreover,esophageal 
variceal ligation during an acute bleed is not associated with a sustained elevation in 
HVPG, as occurs with sclerotherapy.‖ 
                                               ―Endoscopic variceal ligation can cause local 
complications including esophageal ulcers , strictures, and dysmotility,less frequently 
than does sclerotherapy.Banding-induced ulcers can be large and potentially serious if 
gastric fundal varices are banded. A PPI is usually recommended after variceal 
ligation.Detachable snares and clips are generally not indicated.‖ 
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  BALLOON TAMPONADE AND STENTS: 
                  
                 “ From 10% to 15% of patients with an acute variceal bleeding are refractory 
to pharmacologic and endoscopic treatment.Balloon tamponade is used as a 
temporizing measure until TIPS can be carried out. Varices are easily compressed 
because they are superficial and thin-walled and the flow of blood is via submucosal 
vessels. The Sengstaken-Blakemore tube is a triple-lumen tube: one tube is for 
aspirating gastric contents,the other allows inflation of a gastric balloon to 200 to 400 
mL in volume, and the third inflates an esophageal balloon. The Minnesota tube is a 
modified Sengstaken-Blakemore tube. Inflation of a gastric balloon alone is preferred 
with any of these tubes. Balloon tamponade can control bleeding for up to 24 hours in 
approximately 80% to 90% of patients.The risk of pulmonary aspiration is reduced by 
placement of an endotracheal tube. If bleeding cannot be controlled after placement of 
the tube,  reinflate and reposition the gastric balloon than to inflate the esophageal 
balloon.Because of the risks associated with placement of tamponade balloons, self-
expandable metallic covered stents have been used to tamponade esophageal varices. 
These stents may be left in place for up to 2 weeks and then removed.‖ 
TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT: 
                                      ―A ―transjugular intrahepatic portosystemic shunt (TIPS)‖—
also referred to as a transjugular intrahepatic portosystemic stent shunt (TIPSS)—
reduces elevated portal pressure by creating a communication between the hepatic 
vein and an intrahepatic branch of the portal vein. A percutaneous transjugular 
approach is used to insert the shunt. A TIPS functions as a side-to-side portacaval 
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shunt and has been used to treat complications of portal hypertension, mainly variceal 
bleeding and refractory ascites, as well as Budd-Chiari syndrome,hepatic hydrothorax, 
and hepatorenal syndrome‖. 
                                ―TIPS‖ has been used to control acute variceal bleeding and to 
prevent variceal rebleeding when pharmacologic and endoscopic therapies have 
failed, especially in patients with Child-Pugh class B or C cirrhosis, in whom bleeding 
is more likely to be refractory to therapy than in patients with Child-Pugh class A 
cirrhosis. The use of early TIPS (within 72 hours of control of variceal bleeding) in 
patients at high-risk of rebleeding (Child-Pugh class C, class B with active bleeding, 
or a MELD score > 18 and a transfusion requirement of > 4 units of red blood cells 
[RBCs]) is associated with a reduced rate of treatment failure and mortality, without 
an increased risk of hepatic encephalopathy, compared with continued pharmacologic 
and endoscopic therapy. When bleeding from varices cannot be controlled after 2 
sessions of endoscopic therapy within a 24-hour period, TIPS placement is the usual 
salvage treatment.TIPS is also used to treat bleeding from isolated gastric fundal 
varices, for both control of bleeding and prevention of rebleeding. Complications 
following the procedure are classified as procedure related, early (occurring within 
30days),or late (after 30days) ,TIPS cannot be recommended as a first choice for 
preventing variceal rebleeding due to various complications; rather, it is reserved for 
patients who have failed endoscopic or pharmacologic therapy.‖ 
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SURGICAL THERAPY: 
―Surgical treatment of portal hypertension falls into 3 groups:  
 non-shunt procedures 
 portosystemic shunt procedures 
 liver transplantation 
                             Surgical procedures (other than liver transplantation) are used as 
salvage therapy when standard management with pharmacologic and endoscopic 
therapy fails in patients with noncirrhotic causes of portal hypertension and in patients 
with Child-Pugh class A cirrhosis. Liver transplantation should be considered in all 
patients with cirrhosis and variceal bleeding‖ 
 
NON-SHUNT PROCEDURES : 
 
―Non-shunt procedures include ―esophageal transection‖ and ―gastroesophageal 
devascularisation‖. They are performed infrequently but may be required in selected 
cases‖. 
 
SURGICAL SHUNTS: 
                          ― With the increasing availability of TIPS, the use of surgical shunts 
for refractory variceal bleeding has declined markedly.In children, surgical shunts are 
carried out almost exclusively for refractory bleeding due to noncirrhotic portal 
hypertension, such as congenital hepatic fibrosis and portal vein thrombosis. Surgical 
portosystemic shunts are categorized as selective shunts such as distal splenorenal 
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Shunts(WARRENS SHUNT), partial shunts such as the side-to-side calibrated 
portacaval shunt, and total portosystemic shunts such as the side-to-side portacaval 
shunt or end-to-side portacaval shunt.‖ 
 
GASTRIC VARICES TREATMENT: 
  
a. Endoscopic treatment modalities for gastric variceal bleeding.  
1. Gastric variceal sclerotherapy (GVS).  
2. Gastric variceal obturation (GVO) with glue.  
3. Gastric variceal band ligation (GVL) with or without detachable snares.  
4. Thrombin injection (bovine or human).  
5. Combined endoscopic therapy.  
b. Endoscopic ultrasound-guided therapy.  
c. Radiologic intervention – 
 
                                    ― transjugular intrahepatic portosystemic shunt (TIPS)‖ 
 
                                    ― Balloon-Occluded Retrograde Transvenous Obliteration( BRTO)‖. 
 
 
Management Recommendations: 
 
 
 
1)PATIENTS WITH CIRRHOSIS BUT NO VARICES: 
 
 
 
46 
 
2)PATIENTS WITH CIRRHOSIS AND SMALL VARICES, BUT NO 
HEMORRHAGE: 
 
 
 
3)PATIENTS WITH CIRRHOSIS AND MEDIUM OR LARGE VARICES, 
BUT NO HEMORRHAGE: 
 
 
 
―If a patient is placed on a nonselective beta-blocker, it should be adjusted to the 
maximal tolerated dose; follow-up surveillance EGD is unnecessary. It is a cost-
effective form of prophylactic therapy. It does not prevent development or growth 
from small to large varices and  has significant side effects.Patients receiving a 
selective β-blocker (metoprolol, atenolol) for other reasons should switch to a 
nonselective β-blocker (propranolol, nadolol, or carvedilol).‖ 
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                                      ― If a patient is treated with EVL, it should be repeated every 
1-2 weeks until obliteration with the first surveillance EGD performed 1-3 months 
after obliteration and then every 6-12 months to check for variceal recurrence.Nitrates 
(either alone or in combination with beta-blockers), shunt therapy, or sclerotherapy 
should not be used in the primary prophylaxis of variceal haemorrhage.‖ 
 
4)PATIENTS WITH CIRRHOSIS AND ACUTE VARICEAL HEMORRHAGE: 
 
 
 
                              ―In patients who bleed from gastric fundal varices,endoscopic 
variceal obturation using tissue adhesives such as cyanoacrylate is preferred, where 
available.Otherwise, EVL is an option.TIPS should be considered in patients in whom 
hemorrhage from fundal varices cannot be controlled or in whom bleeding recurs 
despite combined pharmacological and endoscopic therapy‖ 
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5)PATIENTS WITH CIRRHOSIS WHO HAVE RECOVERED FROM ACUTE 
VARICEAL HEMORRHAGE: 
 
 
 
RECOMMENDATIONS FOR FIRST-LINE MANAGEMENT OF CIRRHOTIC  
 
PATIENTS AT EACH STAGE IN THE NATURAL HISTORY OF VARICES: 
 
 
                     
 
 
 WHY THERE IS A NEED FOR NONINVASIVE PREDICTORS OF 
 
 ESOPHAGEAL VARICES? 
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                     ―It is shown that nonselective beta-blockers prevent bleeding in more 
than half of patients with medium or large varices but it does not prevent development 
or growth from small to large varices and  has significant side effects. Therefore, it is 
recommended that patients with  cirrhosis undergo endoscopic screening for varices at 
the time of diagnosis.Since the point prevalence of medium/large varices is 
approximately 15%-25%, the majority of subjects undergoing screening EGD either 
do not have varices or have varices that do not require prophylactic therapy. And EGD 
is expensive and usually requires sedation and it can be avoided in patients with 
cirrhosis who are already on nonselective beta-blockers for other reasons (e.g.,arterial 
hypertension).‖  
 
                           ―This approach places a heavy burden upon endoscopy units and the 
repeated testing over time may have a detrimental effect on patient compliance. 
Noninvasive identification of patients at highest risk for oesophageal varices would 
limit investigation to those most likely to benefit. Upper GI endoscopy is deemed to 
be the gold standard against which all other tests are compared, but is not without its 
limitations. There is conflicting evidence with regard to the interobserver agreement 
for endoscopic diagnosis of variceal presence, grade, or presence of red signs . 
Multiple studies have been performed assessing clinical signs and variables relating to 
liver function, variables relating to liver fibrosis, and also to portal hypertension and 
hypersplenism. Whilst some tests are clearly preferable to patients, none appear to be 
as accurate as upper GI endoscopy in the diagnosis of oesophageal varices. The search 
for noninvasive tests continues.” 
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POSSIBLE APPROACHES TO NONINVASIVE DIAGNOSIS OF ESOPHAGEAL 
VARICES: 
1)Physical Signs and Variables Related to Liver Function: 
“A number of clinical signs and other laboratory markers have been identified either 
alone or in combination as factors predicting the presence of oesophageal varices. 
These include the presence of spider naevi, splenomegaly or ascites, Child-Pugh 
classification, serum albumin, and prothrombin time.” 
“Spider naevi, a low-albumin and low-platelet count were shown to be independent 
risk factors for the presence of varices in a study by Garcia-Tsao et al.In a further 
study by Berzigotti et al,spider naevi, ALT, and albumin were found to predict 
oesophageal varices with the best cutoff giving a sensitivity of 93%, specificity of 
37%, and correctly classifying 72% of patients. Similarly, spider naevi have been 
found to be predictive of large oesophageal varices with a diagnostic accuracy of 72% 
when using the variables platelet count, prothrombin index, and spider naevi . 
Chalasani et al.  found that splenomegaly detected on clinical examination was an 
independent risk factor for the presence of large varices. Zaman et al.  demonstrated 
that cirrhotic patients in Child-Pugh classes B or C were almost 3 times as likely to 
have oesophageal varices or large oesophageal varices as compared to patients in 
Child-Pugh class A.” 
The Baveno IV International Consensus Workshop on methodology of diagnosis and 
treatment concluded that no study reached a high enough level of significance to 
warrant the widespread use of such noninvasive markers of oesophageal varices .” 
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2)Variables Related to Liver Fibrosis: 
 
“Chronic liver injury and inflammation leads to fibrosis and ultimately cirrhosis, 
through the deposition of extracellular matrix (ECM) complexes. The collagen fibrils 
of the complex undergo secondary processing, becoming cross-linked, which confers 
resistance to degradative enzymes and irreversibility . Normally, deposition of the 
ECM is a dynamic, reversible process with removal of ECM mediated by several 
specific matrix metalloproteinases (MMPs), which in turn are regulated by soluble 
inhibitors termed TIMPs (tissue inhibitor of metalloproteinase). A number of serum 
markers for ECM deposition and removal have been evaluated as candidate markers 
for liver fibrosis, and a small number of studies have evaluated their usefulness in 
predicting oesophageal varices. Potential markers examined to date include the 
glycoproteins, hyaluronic acid and laminin, and members of the collagen family 
including procollagen III and type IV collagen. Conflicting results have been 
demonstrated. Galal et al.  assessed the ability of serum hyaluronic acid to predict 
medium-to-large oesophageal varices and showed the sensitivity, specificity, positive 
and negative predictive values, and diagnostic accuracy at a cutoff of 207 μg/L to be 
94%, 77.8%, 88.7%, 87.5%, and 88.3%, respectively. Körner et al.  showed no 
association between concentrations of hyaluronic acid or laminin and grade of 
oesophageal varices, and a further study by Bahr et al.  confirmed the lack of 
association of serum laminin to size of oesophageal varices.” 
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“Similar conflict is seen when examining the evidence with regard to the role of the 
collagens. In the first of only 2 studies in this area, the aminoterminal propeptide of 
type III procollagen was shown to have a weak correlation to the degree of 
oesophageal varices . The second study by Mamori et al.  included 44 patients with 
alcoholic liver disease and demonstrated a significant difference in serum type IV 
collagen levels between patients with and without varices (712.3 versus 
404.3 ng/mL,p value<0.001 ), giving an AUROC of 0.78 for predicting the presence 
of oesophageal varices.” 
“None of the aforementioned markers could currently be utilised to predict 
oesophageal varices in portal hypertension; in view of this several different 
biomarkers have been combined with the aim of improving their diagnostic ability. 
FibroTest is a composite score generated by combining the results of five serum blood 
tests (alpha-2-macroglobulin, apolipoprotein A1, haptoglobin, γ-
glutamyltranspeptidase, and bilirubin and alanine) corrected for the age and gender of 
the patient. Results have shown high predictive values for significant fibrosis in 
patients with chronic hepatitis C, chronic hepatitis B, fatty liver disease, and chronic 
alcoholic liver disease . A single study has assessed the predictive value of fibroTest 
in the diagnosis of large oesophageal varices in 99 cirrhotic patients. Significant 
differences in FibroTest value (0.89 versus 0.82), platelet count (110 versus 150), and 
prothrombin time (50 versus 66%) were seen between patients with and without large 
oesophageal varices. FibroTest had the highest discriminative power of all the 
variables with an AUROC curve of 0.77. Using a cutoff of 0.80, this gave a sensitivity 
of 92%, specificity 21%, PPV 33%, and NPV 86%. A fibroTest score < 0.75 was 
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found to be associated with the absence of large oesophageal varices with a NPV of 
100%. The limitations to the study are that it was a retrospective study with significant 
population bias and has not been reproduced in a prospective study of compensated 
cirrhotics. FibroTest is not readily available to most clinicians, which limit its utility 
as a screening test.” 
 
3)Variables Related to Portal Hypertension and Hypersplenism: 
 
“Thrombocytopenia may occur in portal hypertension-induced splenomegaly, in part 
due to platelet sequestration, and a large number of studies have been performed 
assessing the relationship between platelet count and oesophageal varices. A low-
platelet count is regularly identified as predictive of oesophageal varices and large 
oesophageal varices, but there is a wide variation in the cut-off level of platelets used, 
ranging from 68,000 to 160,000 with sensitivities ranging from 71–90% and 
specificities from 36–73%. Bias is likely to account for much of this variation, with 
the majority of studies being retrospective in nature, having heterogeneous cohorts of 
patients resulting in both selection and spectrum bias.” 
“A longitudinal study by Qamar et al.  of 213 patients, with compensated cirrhosis 
with portal hypertension but without varices, demonstrated that the median platelet 
count at the time of occurrence of varices was 91,000. However, no platelet count 
could be identified that accurately predicted the presence of oesophageal varices 
(AUROC curve 0.63), and they, therefore, concluded that platelet count is an 
inadequate noninvasive marker for prediction of the presence of oesophageal varices.” 
54 
 
“In an attempt to improve the predictive value of the platelet count, it has been 
combined with other variables, and the results of these studies are discussed below. 
Oesophageal collaterals develop as a consequence of portal hypertension, being 
formed by vascular remodelling and angiogenesis. Key molecules thought to be 
involved in this include nitric oxide and vascular endothelial growth factor (VEGF). A 
single study of 85 cirrhotic patients examined the predictive capability of serum 
nitrate levels to detect oesophageal varices . Significant differences in serum nitrate 
levels were found between patients with large oesophageal varices compared to 
patients without oesophageal varices. The best cut-off level for prediction of 
oesophageal varices was 38 μmol/L, giving a sensitivity 86.5%, specificity 83.3%, 
PPV 95%, and NPV 62.5%. Animal studies suggest that the formation of oesophageal 
varices results not only from opening up of preexisting collateral vessels but also as a 
result of angiogenesis which may in part be mediated by VEGF. Use of VEGF as a 
noninvasive biomarker has only been investigated in a single study, and no correlation 
between VEGF levels and grade of oesophageal varices was detected .” 
“The development of portosystemic collaterals and the resultant shunting is 
responsible for the complication hepatic encephalopathy, in which ammonia plays a 
role. One study has examined the role of blood ammonia concentrations in the 
noninvasive detection of oesophageal varices . In this study of 153 cirrhotic patients, a 
significant correlation was demonstrated between oesophageal variceal grade and 
venous ammonia levels. The AUROC curve for predicting the presence of 
oesophageal varices was 0.78, and using a cut-off of 42 μM/L this gave a sensitivity of 
92% and a specificity of 60%.” 
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Therefore, variables associated with portal hypertension and hypersplenism are not 
accurate enough to be used as noninvasive markers of oesophageal varices.” 
PREDICTIVE SCORES: 
1.Platelet count /spleen diameter Ratio:  
 
―This ratio is calculated by dividing the platelet number/mm by the maximum spleen 
bipolar diameter in mm as estimated by abdominal ultrasound. There have now been a 
number of studies assessing this. The first by Giannini et al. in 2003, reported the 
platelet count/spleen diameter ratio to be the only independent variable associated 
with presence of OV on multivariate analysis and identified a cut-off value of 909, 
giving a PPV of 96% and NPV of 100% . The second part of the study confirmed the 
reproducibility of this cut-off level with a PPV of 74% and NPV of 100% in 
compensated cirrhotic patients. The same group then followed up 68 patients without 
OV with repeat endoscopy and calculation of the platelet/spleen diameter ratio. At 
followup, patients with a platelet count/spleen diameter ratio < 909 had 100% NPV 
and 84% PPV, and they concluded that the platelet count spleen diameter ratio was 
effective in ruling out the presence of OV when cirrhotic patients were followed 
longitudinally.‖ 
 ―Subsequently, a multicentre, international validation study using the 909 ratio was 
performed in 218 patients. The test performed less well than in the original study with 
a PPV of 76.6% and a NPV of 87.0%. This has been a consistent feature in all studies 
subsequently performed which vary from being retrospective or prospective in nature 
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and utilise different cut off points . Therefore, despite promising early results the 
platelet count/spleen diameter ratio is not a reliable tool to screen for oesophageal 
varices.‖ 
(2) Platelet Count and Child-Pugh Class  
 
―In 2007, Burton et al. published the validation of a model for predicting size and 
presence of varices based upon platelet count and Child-Pugh class . The first model 
aimed to detect large varices in Child-Pugh A patients with a platelet count <80 and 
had a sensitivity of 58%, specificity 79%, PPV 30%, and NPV 92%. The second 
model aimed to identifying any varices in Child B/C patients with a platelet count <90 
and had a sensitivity of 60%, specificity of 59%, PPV 80%, and NPV 34%. Once 
again, the performance of these models would not reliably predict the presence of 
oesophageal varices.‖ 
 2)AST/ALT Ratio 
 
―The AST/ALT ratio has been used to predict cirrhosis, and by natural extension 
studies have been performed to assess its usefulness in predicting oesophageal varices. 
In a retrospective study , significantly higher AST/ALT ratios were seen in patients 
with varices compared to those without (ratio: 1.8 versus 1.0 ). A further prospective 
study found an AST/ALT ratio > 1.12 to be significantly associated with the presence 
of varices at initial endoscopy (OR 3.9,  95% CI 1.3–11.8). This cutoff gave a 
sensitivity of 47.8%, specificity of 87%, PPV 42.3%, and NPV 89.2%, and an 
AUROC of 0.69. A further study using a different cut-off of ≥1.0 demonstrated a 
sensitivity of 68%, specificity of 89%, PPV 77%, and NPV 83%, with an AUROC 
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0.83 (0.72–0.94) for predicting the presence of oesophageal varices . For the 
prediction of large oesophageal varices, this gave a sensitivity 68%, specificity 77%, 
PPV 41%, and NPV 92%, and AUROC 0.79 (0.64–0.94). Overall, the AST/ALT ratio 
correctly classified 81% patients for the detection of varices and 76% of those with 
large varices. Therefore these studies, which include patients with different aetiologies 
of liver disease and used different cutoffs for the AST/ALT ratio cannot confidently 
predict the presence of oesophageal varices in clinical practice to avoid screening all 
cirrhotic patients with endoscopy.‖ 
 
(4) Right Lobe Liver Albumin Ratio 
 
―This ratio is calculated by dividing the right liver lobe diameter (as assessed by 
abdominal ultrasound and measured in millimetres) by the serum albumin 
concentration (g/L). This has been assessed in a single study of 94 cirrhotic patients. 
Right liver lobe/albumin ratio correlated with presence and size of oesophageal 
varices. For a cut-off value of 4.425 this gave a sensitivity of 83.1% and specificity 
73.9% and thus once again cannot be used as a reliable screening test.‖ 
 Liver Stiffness 
“Transient elastography (TE, FibroScan, Echosens, France) is a noninvasive technique 
developed to assess hepatic fibrosis in patients with chronic liver diseases. Fibrosis 
causes an increase in liver stiffness, and measurement of this forms the basis of TE, 
which is painless, rapid, and easy to perform. A wide range of liver stiffness values 
have been reported ranging from 2.5 to 75 kPa, being influenced by gender, body 
mass index, disease aetiology, and presence of necroinflammatory change . As a 
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rough guide, normal TE values are considered to be 3.8–8 kPa in men and 3.3–7.8 kPa 
in women, significant fibrosis (Metavir fibrosis stage ≥ 2) 7-8 kPa and cirrhosis 13–
17 kPa.Another parameter was APRI which showed no significant correlation. 
Studies demonstrate a significant correlation between liver stiffness measurements 
and the presence of oesophageal varices but are divided with regard to the relationship 
of liver stiffness to variceal size. Therefore, the predictive performance of liver 
stiffness measurement is poor for the diagnosis of OV with low specificity and PPV, 
particularly with regard to large OV. However, it may be useful as a screening test to 
identify patients in whom variceal screening is not required.” 
 
“Portal vein diameter, portal blood velocity and congestion index, spleen size, flow 
pattern in the hepatic veins, and the presence of abdominal portosystemic collaterals 
are all US parameters previously thought to have with prognostic significance but all 
with poor sensitivity and specificity .Use of CT as the initial screening modality for 
the detection of varices was significantly cost effective compared to endoscopy 
irrespective of the prevalence of large varices.” 
 
“Capsule endoscopy is feasible in the majority of patients and with regard to patient 
preference, capsule endoscopy appears to be preferable to conventional endoscopy 
and may improve compliance with screening programmes, although this remains to be 
determined and cost effectiveness is a major factor.” 
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“In conclusion, based on all the available evidence to date, upper GI endoscopy 
remains the gold standard for the diagnosis of oesophageal varices in cirrhotic patients 
despite its own limitations. Clinical, biochemical, and radiological parameters 
currently are not accurate enough to avoid screening endoscopy, due to the risks 
associated with missing patients with large oesophageal varices. In a limited 
resources setting like ours,where financial constraints are a major 
problem,predicting the presence and grade of varices by non-invasive methods 
serves to help a lot in various ways‖ 
―The common features of these noninvasive means that prediction of 
esophageal varices is reproducible, cost effective, simple and quick with no 
additional burden to patients. Even though these variables are clearly preferable 
to patients, none is comparable to UGIE in terms of sensitivity and specificity in 
prediction of variceal hemorrhage. To improve the sensitivity and specificity in 
variceal prediction, several predictive models are proposed using various 
combinations of the above variables. Apparently,the sensitivity and specificity 
of the currently proposed predictive models varies with population, the 
etiologies of liver cirrhosis and the severity of liver disease.‖ 
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MATERIALS AND METHODS 
 
STUDY POPULATION: 
The present study was conducted on 50 patients admitted  with a diagnosis of 
cirrhosis of liver at general medicine and medical gastroenterology wards of  
Government Rajaji Hospital, Madurai during the period of  February 2016 to 
July 2016. 
INCLUSION CRITERIA: 
50 patients admitted with a diagnosis of cirrhosis of liver to the general 
medicine and medical gastroenterology wards of Government Rajaji 
Hospital,Madurai.Diagnosis of cirrhosis was based on clinical, biochemical 
and ultrasonographic findings. 
EXCLUSION CRITERIA:  
Individuals presenting with  
 variceal bleed 
  those with a past history of bleed and who had undergone 
sclerosis or band ligation of esophageal varices 
  portal vein thrombosis, Hepatoma  
 on current or past treatment with beta-adrenergic receptor 
blockers. 
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DATA COLLECTION: 
A previously designed proforma was used to collect the demographic and 
clinical details of the patients.  All the patients  underwent  detailed clinical 
evaluation, appropriate investigations, imaging studies (ultrasound with 
Doppler) and upper g.i endoscopy. 
STUDY PROTOCOL: 
DESIGN OF STUDY: 
                     Observational Cross sectional study 
PERIOD OF STUDY: 
February  2016 To July 2016 ( 6 months) 
METHODOLOGY: 
History was taken on details and duration of alcoholism, jaundice, ascites, 
oliguria, pedal edema and gastrointestinal bleed. Presence or absence of 
jaundice, ascites, splenomegaly and hepatic encephalopathy was noted. 
Platelet count, prothrombin time and INR,liver function tests including 
serum bilirubin, serum transaminases, serum albumin was estimated. 
Modified Child-Turcotte-Pugh (CTP) class was calculated for each patient. 
At ultrasonogram abdomen and Doppler study of portal venous system, the 
portal vein and spleen diameter along with echo texture of the liver,spleen 
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size and direction of blood flow,ascites was noted. The portal vein diameter 
and platelet count / spleen diameter ratio was  determined. At UGI 
endoscopy, the esophageal varices was graded as large (Grade III-IV) or 
small (Grade I-II), based on Paquet’s grading system. 
 LABORATORY INVESTIGATIONS: 
                             Platelet count,liver function tests including serum 
bilirubin, albumin,globulin,transaminases, prothrombin time and INR.  
COLLABORATING DEPARTMENTS: 
Department Of  Medical Gastroenterology 
Department Of  Biochemistry 
Department of  Radiology 
ETHICAL CLEARANCE: Clearance obtained 
CONSENT: Individual written and informed consent obtained. 
STATISTICAL ANALYSIS:  
All data were entered in Excel 2007 and statistical analysis was performed using 
the statistical software SPSS 16.0.Data were expressed as frequency (with 
percentages), median values (with range (min, max)). For continuous variables, 
Mann Whitney U-test was performed to find the differences between two groups 
and for categorical variables Pearson’s chi-square test was performed.Results were 
defined as statistically significant when the P value (2-sided) was less than 0.05 
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RESULTS AND OBSERVATIONS 
            Table 1.Age distribution of the study population (n -50) 
 
Varices Grade 
Small (Grade I-II) 
or no varices 
Large varices 
(Grade III-IV)  
N=28 N=22 
Median Range Median Range 
Age (in yrs) 48 (17 – 72) 50 (26 – 73) 
 
COMMENTS: 
Out of 50 total patients,28 had small varices and 22 had large varices. 
In small varices group,median age was 48 (17 -72),in large varices group 
median age was 50(26-73). 
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                Table 2. Gender distribution of the study population (n-50) 
Gender 
Varices Grade 
Small (Grade I-II) 
or no varices 
Large varices 
(Grade III-IV)  
No % No % 
Male 20 71.4 17 77.3 
Female 8 28.6 5 22.7 
Total 28 100.0 22 100.0 
 
 COMMENTS: 
In small varices group,20 patients were male and 8 patients were female.  In large 
varices group,17 patients were male and 5 patients were female. 
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               Table 3:Distribution of varices based on etiology 
 
Etiology 
Varices Grade 
Small (Grade I-II) 
or no varices 
Large varices 
(Grade III-IV)  
No % No % 
Alcohol 7 25.0 12 54.5 
Wilsons 1 3.6 - - 
HBV 5 17.9 2 9.1 
HCV 2 7.1 1 4.5 
Alcohol+HBV 2 7.1 1 4.5 
Alcohol+HCV 2 7.1 1 4.5 
Others 9 32.1 5 22.7 
Total 28 100.0 22 100.0 
p-value P=0.531 (Not Significant) 
 
COMMENTS: 
Alcohol was the most common etiology and out of 19 patients 12 had large varices. 
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                Table 4:Distribution of varices according to Child pugh class 
 
CTP Class 
Varices Grade 
Small (Grade I-II) 
or no varices 
Large varices 
(Grade III-IV)  
No % No % 
Class A 21 75.0 3 13.6 
Class B 5 17.9 7 31.8 
Class C 2 7.1 12 54.5 
Total 28 100.0 22 100.0 
p-value p<0.001 (Significant) 
 
COMMENTS: 
In no/small varices group,75% were in CTP –A,17.9%  were in CTP-B and 
7.1% belonged to CTP-C class. 
In large varices group, 13.6%  were in CTP-A, 31.8% were in  CTP-B , 54.5% 
were in CTP-C class. 
P value <001,significant ,so presence of large gastroesophageal varices correlated 
with the severity of liver disease,as child pugh class C has maximum  no of large 
varices. 
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              Table 5:Distribution of varices according to grade of ascites  
 
 
Ascites 
Varices Grade 
Small (Grade I-II) 
or no varices 
Large varices 
(Grade III-IV)  
No % No % 
Nil 11 39.3 3 13.6 
Mild 13 46.4 2 9.1 
Moderate 3 10.7 10 45.5 
Massive 1 3.6 7 31.8 
Total 28 100.0 22 100.0 
p-value p<0.001 (Significant) 
 
COMMENTS: 
Large varices were associated with increasing grade of ascites ,p value<0.001 
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Table 6 : Correlation of varices grade with platelet count             
 
Varices Grade 
Small (Grade I-II)  
or no varices 
Large varices  
(Grade III-IV)  
N=28 N=22 
Median Range Median Range 
Platelet Count 200000 (42000 – 442000) 90100 (28000 – 245000) 
p-value p<0.001 (Significant) 
 
COMMENTS: median platelet count in large varices group was 90,100 
                       median platelet count in small varices group was 2 lakh. 
With a p value <0.001,low platelet count was significantly associated with large 
varices.  
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  Table 7:Correlation of  varices grade with  bilirubin levels           
 
Varices Grade 
Small (Grade I-II)  
or no varices 
Large varices  
(Grade III-IV)  
N=28 N=22 
Median Range Median Range 
Total Bilirubin (mg/dl) 1.2 (0.4 – 19.4) 2.8 (0.2 – 10.2) 
p-value p=0.001 (Significant) 
 
COMMENTS: 
  Large varices were significantly correlated with increasing bilirubin levels.(p value-     
0.001) 
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          Table 8: Correlation of  varices grade with  serum albumin levels 
 
Varices Grade 
Small (Grade I-II)  
or no varices 
Large varices  
(Grade III-IV)  
N=28 N=22 
Median Range Median Range 
Albumin (g/dl) 3.7 (2.2 – 4.8) 2.2  (1.6 – 3.9) 
p-value p<0.001 (Significant) 
 
 
 COMMENTS: 
Large varices were significantly correlated with  low albumin levels.(p value-  0.001) 
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    Table 9: Correlation of  varices grade with  prothrombin time 
 
Varices Grade 
Small (Grade I-II)  
or no varices 
Large varices  
(Grade III-IV)  
N=28 N=22 
Median Range Median Range 
Prothrombin Time 
(seconds prolonged) 
2.0 (0.4 – 13.0) 3.6 (0.8 – 12.0) 
p-value p=0.004 (Significant) 
 
COMMENTS: 
Large varices were significantly correlated with  elevated prothrombin time .(p value-  
0.004) 
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  Table 10: Correlation of  varices grade with  portal vein diameter.              
 
Varices Grade 
Small (Grade I-II)  
or no varices 
Large varices  
(Grade III-IV)  
N=28 N=22 
Median Range Median Range 
Portal Vein diameter 
(mm) 
12.0 (8.0 – 15.2) 15.6 (10.8 – 22.4) 
p-value p<0.001 (Significant) 
 
COMMENTS: 
Large varices were significantly correlated with  increasing portal vein diameter (p 
value-  0.001). 
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         Table 11: Correlation of  varices grades with spleen size.      
 
Varices Grade 
Small (Grade I-II) or 
no varices 
Large varices  
(Grade III-IV)  
N=28 N=22 
Median Range Median Range 
Spleen size 
(mm) 
142.0 (92 – 218) 182.5 (140 – 258) 
p-value p<0.001 (Significant) 
 
COMMENTS:Large varices were significantly correlated with  increasing spleen size 
(p value-  0.001) 
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Table 12: Correlation of  varices grades with platelet count/spleen diameter ratio.        
 
Varices Grade 
Small (Grade I-II)  
or no varices 
Large varices  
(Grade III-IV)  
N=28 N=22 
Median Range Median Range 
Platelet Count\ 
Spleen diameter ratio 
1477.6 (300.0 – 4804.3) 454.1 (144.3 – 1601.3) 
p-value p<0.001 (Significant) 
 
COMMENTS: 
Large varices were significantly correlated with  lower values of platelet count/spleen 
diameter ratio.(p value-  0.001) 
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DISCUSSION 
 Our study was done to assess various noninvasive predictors that could predict 
the presence of large esophageal varices. 
 Out of 50 total patients,28 had small varices and 22 had large varices. 
 In small varices group,median age was 48 (17 -72),in large varices group 
median age was 50(26-73). 
 In small varices group,20 patients were male and 8 patients were female,in 
large varices group,17 patients were male and 5 patients were female.  
 
 Alcohol was the most common etiology and out of 19 patients 12 had large 
varices 
 
 In no/small varices group,75% were in CTP –A,17.9%  were in CTP-B and 
7.1% belonged to CTP-C class.In large varices group, 13.6%  were in CTP-A, 
31.8% were in  CTP-B , 54.5% were in CTP-C class.P value <001,significant 
so presence of large gastroesophageal varices correlated with the severity of 
liver disease,as child pugh class C has maximum  no of large varices. 
 
 Large varices were associated with increasing grade of ascites ,p value<0.001 
median platelet count in large varices group was 90,100,median platelet count 
in small varices group was 2 lakh.With a p value <0.001,low platelet count was 
significantly associated with large varices 
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 Large varices were significantly correlated with increasing bilirubin 
levels,median value- 2.8 mg/dl.(p value-  0.001) 
 Large varices were significantly correlated with  low albumin levels,median 
value -2.2 mg/dl.(p value-  0.001) 
 Large varices were significantly correlated with  elevated prothrombin 
time,median value – 3.6 sec prolonged .(p value-  0.004) 
 Large varices were significantly correlated with  increasing portal vein 
diameter,median value- 15.6 mm (p value-  0.001). 
 Large varices were significantly correlated with  increasing spleen size,median 
value -182.5 mm (p value-  0.001) 
 Large varices were significantly correlated with  lower values of platelet 
count/spleen diameter ratio.,with a median value of 454.1(p value-  0.001) 
 
                        Large esophageal varices are a dangerous clinical consequence of liver 
cirrhosis. Since variceal screening causes considerable endoscopic burden and cost, 
seeking a less expensive, noninvasive means for accurate prediction of large 
esophageal varices has great clinical importance. Several studies in the past have 
shown independent parameters like splenomegaly, ascites, spider naevi, Child’s 
grade,platelet count, prothrombin time/activity, portal vein diameter,platelet count/ 
spleen diameter ratio,serum albumin, and serum bilirubin as significant predictors for 
the presence of esophageal varices. 
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The present study further corroborates the results of earlier studies. Giannini et 
al,proposed the platelet count-spleen diameter ratio of ≤ 909, as an accurate non-
invasive marker for the presence of esophageal varices. This was further validated in a 
multicenter trial. The study population comprised predominantly of patients with 
hepatitis C related cirrhosis. A similar study by Agha et al, from Pakistan, made 
identical observations in the same subset of patients. Sen et al, found the platelet 
count-spleen diameter ratio of ≤ 650 as a sensitive non-invasive marker [Area under 
curve (AUC) of 0.81] in HCV related cirrhosis. 
Non endoscopic assessment for presence and grades of varices from India are few. 
Amarapurkar et al, report that splenomegaly alone was a significant predictor for the 
development of large esophageal varices. Sharma et al, in a prospective study, 
observed that splenomegaly and platelet count were the independent predictors for the 
presence of large varices. They could derive a predictor function based on this 
observation, which had an AUC of 0.76. 
From the present study, Child Pugh class B/C,presence of higher grades of 
Ascites,low platelet count,low serum albumin,high total bilirubin,elevated 
prothrombin time,higher portal vein diameter,higher spleen size ,lower platelet count 
/spleen diameter ratio emerged as significant predictors for the presence of large 
esophageal varices.  
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CONCLUSION 
1) Child Pugh class B/C,presence of higher grades of Ascites,low platelet 
count,low serum albumin,high total bilirubin,elevated prothrombin time,higher 
portal vein diameter,higher spleen size ,lower platelet count /spleen diameter 
ratio emerged as significant predictors for the presence of large esophageal 
varices. 
2) Presence and Grade of varices  was correlated with severity of liver diseases as 
in large varices group, 13.6%  were in CTP-A, 31.8% were in  CTP-B , 54.5% 
were in CTP-C class. 
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SUMMARY 
A cross sectional observational study was done at Government Rajaji Hospital, 
Madurai among 50 cirrhosis of liver patients for assessing various noninvasive 
predictors that could predict the presence of large esophageal varices. From the 
present study, Child Pugh class B/C,presence of higher grades of Ascites,low platelet 
count,low serum albumin,high total bilirubin,elevated prothrombin time,higher portal 
vein diameter,higher spleen size ,lower platelet count /spleen diameter ratio emerged 
as significant predictors for the presence of large varices. We believe that these 
predictors may be of help to the physicians practicing in  areas where endoscopy 
facilities are not readily available, in helping them to initiate appropriate primary 
pharmacological prophylaxis in these patients. Accurate identification of patients at 
the highest risk of bleeding allows stratification in an attempt to avoid unnecessary 
preventive measures in 60-75% of patients who will never have variceal bleeding in 
future. In a limited resources setting like ours,where financial constraints are a major 
problem,predicting the presence and grade of varices by non-invasive methods help to 
avoid unnecessary upper G.I endoscopies. 
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PROFORMA 
Name: 
Age / Sex: 
IP no: 
Occupation: 
 
Presenting complaints: 
h/o,jaundice, ascites, oliguria, pedal edema , gastrointestinal bleed, altered 
sensorium. 
 
Past History: 
h/o Jaundice, blood transfusion, tattoing, iv drug use, sexual promiscuity 
h/o CLD, DM, HT, CKD, CVD, DRUG INTAKE, THYROID 
DISORDERS,EPILEPSY,HEPATITIS.  
 
Personal history 
alcoholic/ non alcoholic 
smoker/ nonsmoker 
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Clinical Examination: 
General Examination: 
Consciousness, orientation, febrile/afebrile, Pallor, jaundice, Clubbing, 
Lymphadenopathy, pedal edema. 
Vitals: 
PR 
BP 
RR 
SpO2 
Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
Laboratory investigations: 
1.platelet count 
2.LFTs including serum bilirubin,albumin,globulin,transaminases,    
3. prothrombin time and INR. 
 
Diagnosis 
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LIST OF ABBREVIATION 
LFT-liver function test 
AST- Aspartate aminotransferase 
ALT- Alanine aminotransferase 
UGI- Upper Gastrointestinal 
MELD- Model for End stage Liver Disease score 
CTP-child turcotte pugh 
PT-prothrombin time 
TIPSS- Transjugular Intrahepatic Portosytemic Shunt Surgery 
BRTO-balloon retrograde transvenous obliteration 
NO Nitric Oxide 
GV-gastric varices 
EVL-endoscopic variceal ligation 
EGD-esophago gastroduodenoscopy 
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                                            MASTER CHART 
 
 
sno name age sex etiology platelet ct t.bilirubin albumin PT ascites ctpclas Pvdiameter spleensize PC/SD ratio vergrad
1 Ramalingam 56 M Alcohol 92000 2.1 2.4 8 Massive Class C 12 176 522.72 Grade IV
2 Mari 43 M Alcohol+HBV 1,28,000 0.6 3.1 4.2 Mild Class B 12 152 842.1 Grade II
3 Ibrahim 48 M Alcohol 1,43,000 1.8 1.8 12 Moderate Class C 18.1 200 715 Grade III
4 Durairaj 28 M Wilsons 3,12,000 0.4 3.6 3 NIl Class A 11.8 130 2400 No
5 karthick 29 M Alcohol 1,06,000 2.2 3.2 2.2 NIl Class A 14 166 638.55 No
6 muniyammal 48 F HBV 87,000 2.6 2.8 1.4 Moderate Class B 16.2 180 483.33 Grade III
7 Mokkasamy 40 M HCV 1,02,000 5.8 2 2.4 Massive Class C 20 240 425 Grade IV
8 Nagaraj 45 M Alcohol 55,000 2.4 2.2 5 NIl Class B 10.8 258 213.17 Grade III
9 Ponnathal 50 F Others 2,45,000 0.9 3.6 2.1 NIl Class A 20.2 153 1601.3 Grade III
10 Arumainathan 56 M Others 2,00,000 0.5 3.8 3.2 NIl Class A 8.2 100 2000 Grade I
11 Rajeshwari 64 F Others 3,46,000 0.9 2.8 1.6 NIl Class A 15 142 2436.61 Grade II
12 pandi 50 M Alcohol 28,000 4.6 2.5 5.8 Massive Class C 18 194 144.32 Grade III
13 sundar 35 M Alcohol+HCV 1,29,000 2.8 2.4 3.1 Mild Class B 15.2 154 837.66 Grade I
14 sathyabama 17 F Others 42,000 19.4 2.2 13 Moderate Class C 10 140 300 Grade II
15 rajendran 32 M Alcohol 4,42,000 0.8 3.8 1.1 Mild Class A 8 92 4804.34 Grade I
16 karthika 38 F HBV 116000 4.6 2.4 4.8 Moderate Class B 12.6 218 532.11 Grade II
17 jayabalan 62 M Alcohol 232000 5.2 3.0 3.6 Moderate Class B 13.7 158 1468.35 Grade III
18 jafar 60 M HBV 300000 1.8 4.4 1.4 NIl Class A 11.4 122 2459.01 No
19 marimuthu 54 M Alcohol+HCV 223000 6.8 2.2 2.8 Massive Class C 22.4 186 1198.92 Grade III
20 alagappan 48 M Others 192000 2.2 3.6 2.0 NIl Class A 8.6 136 1411.76 Grade I
21 karusamy 37 M Alcohol 68800 8.2 2.0 4.2 Moderate Class C 15.8 176 390.90 Grade IV
22 lakshmi 56 F Others 335000 0.7 3.8 1.0 Mild Class A 14.0 144 2326.38 No
23 alagar 44 M Alcohol 167000 2.0 3.2 3.4 Moderate Class B 18.6 232 719.82 Grade III
24 thavasithevar 50 M HBV 213000 0.4 4.2 1.6 NIl Class A 15.0 138 1543.47 Grade I
25 shakunthala 48 F Others 100000 1.6 4.0 1.4 Mild Class A 12.6 122 819.67 No
26 kannan 56 M Alcohol 37300 0.2 3.1 0.8 NIl Class A 13.7 185 201.62 Grade IV
27 masilamani 38 M Alcohol+HBV 88200 6.7 2.0 8.2 Moderate Class C 22.4 232 380.17 Grade IV
28 shankarapandi 40 M HCV 152000 3.4 2.8 4.2 Massive Class C 15.2 148 1027.02 Grade I
29 chinnasamy 72 M HBV 223400 1.2 4.0 2.4 Mild Class A 13.0 176 1269.31 Grade I
30 sonai 65 M Alcohol 213600 1.0 3.9 1.0 Mild Class A 13.8 130 1643.07 Grade II
31 gomathi 42 F HBV 112000 2.3 3.2 2.0 Mild Class B 11.8 142 788.73 Grade II
32 alagu 45 F Others 67400 4.0 2.7 1.9 Massive Class C 19.8 166 406.02 Grade IV
33 karuppan 56 M Others 135600 1.8 3.9 2.4 Mild Class A 16.0 162 837.03 Grade III
34 tamilselvan 70 M Alcohol 415000 0.6 4.0 1.8 NIl Class A 12.0 124 3346.77 Grade II
35 ganesan 45 M Others 223700 0.7 4.2 0.4 Mild Class A 14.0 132 1694.69 No
36 karuppayi 55 F Others 155000 1.2 3.6 1.0 Mild Class A 8.2 189 820.10 Grade I
37 pitchai 60 M Others 189000 2.5 3.2 2.9 NIl Class A 13.2 100 1890.00 Grade I
38 velammal 43 F HCV 200000 2.8 3.0 3.2 Moderate Class B 11.4 125 1600.00 Grade II
39 karuppanan 73 M Alcohol 32800 4.9 2.0 5.0 Moderate Class C 12.6 175 187.42 Grade IV
40 natarajan 57 M Alcohol 43000 10.2 1.8 6.8 Massive Class C 14.3 216 199.07 Grade IV
41 veerayi 40 F HBV 98600 2.1 1.6 3.2 Moderate Class B 11.2 140 704.28 Grade III
42 swaminathan 46 M Alcohol 256000 1.8 3.9 2.0 Mild Class A 10.6 152 1684.21 Grade II
43 innasi 53 M Alcohol+HBV 167800 0.4 4.8 1.8 Mild Class A 9.0 143 1173.42 Grade I
44 madhanagopal 54 M Alcohol 132700 3.0 2.2 3.6 Mild Class B 12.8 172 771.51 Grade III
45 ramu 58 M Alcohol 76200 2.2 2.0 5.2 Massive Class C 15.5 186 409.67 Grade IV
46 nagusamy 66 M Alcohol+HCV 334500 1.0 3.6 3.0 NIl Class A 12.2 150 2230.00 No
47 chandrakumar 44 M Alcohol 234500 1.5 4.0 2.5 Mild Class A 10.6 175 1340.00 Grade II
48 bharathi 58 F Others 112000 2.6 2.6 1.8 Moderate Class B 13.8 154 727.27 Grade III
49 bose 26 M Others 84320 4.6 2.1 4.0 Moderate Class C 15.0 200 421.60 Grade IV
50 kumaravel 62 M Alcohol 132000 1.0 3.8 1.4 NIl Class A 10.0 148 891.89 Grade I
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